License to Cure for Medical Device
Accelerate the delivery of innovative, safe and fully compliant medical devices
Transforming medical devices with sustainable innovation.
Learn how to enhance global collaboration, making compliance and innovation complementary processes that contribute to each other’s success.
The process of dealing with quality issues such as Corrective and Preventive Actions (CAPA) and product complaints is the single greatest source of regulatory risk for medical device manufacturers today.
The Dassault Systèmes 3DEXPERIENCE® platform solutions provide medical device manufacturers with the ability to effectively and efficiently manage quality issues by improving traceability and QSR/GMP/ISO compliance while eliminating non-value-added activities. This can help companies avoid compliance risk, reduce waste and deliver unmatched quality, safety and efficacy.
By leveraging the 3DEXPERIENCE platform that combines engineering, quality and regulatory compliance business processes, we have moved closer towards becoming the R&D and manufacturing center of choice for our customer.
Medical device manufacturers are learning to deliver superior personalized, patient-centric experiences that improve patient health. This shift in innovation is focused on both the therapies and medical technologies they create as well as the processes that support their ecosystem.
The 3DEXPERIENCE® platform allows medical device manufacturers to deliver unmatched patient and physician experiences by connecting voice-of-the patient data; delivering life-like, multi-scale and multi-physic models; enabling an end-to-end virtual environment for accelerated collaborative innovation.
The 3DEXPERIENCE® platform along with CATIA Imagine & Shape provided Otto Bock the ability to design their prothese to be as natural as possible.
During the last decade, medical device companies have been divided into numerous isolated divisions. To manage this, many created complex matrix-based organizations attempting to enhance cross-division communication and data exchange to streamline internal processes, but much more is required.
Organizations that digitalize their businesses and leverage digital continuity across the entire innovation continuum will win. This will transform the way they innovate and operate, driving significantly enhanced margins with patient centric experiences and increased productivity and profits.
We selected Dassault Systèmes’ ‘License to Cure for Medical Device’ to help us better manage regulatory activities and new product development as we expand internationally and must meet different market requirements.
As medical device companies look to leapfrog their competition by accelerating innovation, maximizing ROI and creating new, connected patient experiences, leaders will see significant growth in collaborative invention and new models will emerge throughout manufacturing and value chain beyond CROs, CMOs and traditional supply chains.
Services-based experiences will provide for more intelligent, efficient and collaborative open innovation and medical device companies will drive toward more personalized experiences, embracing the consumerization of health.
Leaders in the medical device industry must continually evaluate how to improve manufacturing processes to drive efficiency, quality and performance. Leveraging digital design and production processes presents an opportunity to accelerate innovation and new product introduction.
With the 3DEXPERIENCE platform’s digital manufacturing planning and execution solutions, medical device companies can synchronize global manufacturing networks, deliver agile manufacturing and planning operations, offering real-time visibility and control over the business processes performed by plants and suppliers.
Dassault Systèmes has served Medical Device companies over the last 20+ years helping leaders create and launch breakthrough innovations. From Class I, Class II and Class III – our solutions allow device companies to accelerate the rate of innovation while maintaining total quality and reducing regulatory risk.